14 unchanged sentences
Defendants filed a motion to dismiss the third amended complaint on June 3, 2024.
−Removed: A hearing on the motion to dismiss is currently set for October 3, 2024.
−Removed: We believe the plaintiff’s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.
+Added: The case was dismissed with prejudice on September 12, 2024.
+Added: On October 9, 2024, plaintiff appealed the District Court's dismissal of the case to the Ninth Circuit.
+Added: We believe the plaintiffs' claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.
On December 7, 2021 and March 29, 2022, two verified shareholders derivative lawsuits were filed in the U.S.
8 unchanged sentences
On October 25, 2022, the parties filed a stipulation to consolidate and stay the Go and Morris actions, and on October 27, 2022, the court consolidated the Go and Morris action and stayed the consolidated action pending resolution of the anticipated motion(s) to dismiss in the Securities Class Action.
−Removed: We believe the plaintiff’s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.
+Added: The consolidated case remains stayed pending resolution of the appeal in the Securities Class Action.
+Added: We believe the plaintiffs' claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.
On July 17, 2024, the Company, in partnership with the American Association of Kidney Patients (AAKP) and the National Minority Quality Forum (NMQF), filed a lawsuit in the U.S.
3 unchanged sentences
The Company, AAKP and NMQF are seeking relief under the Administrative Procedure Act to enjoin CMS from proceeding with its plan to include XPHOZAH in the ESRD PPS and eliminate coverage under Medicare Part D beginning on January 1, 2025.
+Added: On September 17, 2024, defendants filed a Motion to Dismiss, the case, and on September 19, 2024, plaintiffs filed a Motion for Preliminary Injunction or, in the Alternative, for Expedited Summary Judgment.
+Added: On August 16, 2024, a complaint was filed against the Company in the U.S.
+Added: District Court of Massachusetts, captioned Yarborough v.
+Added: Ardelyx, Inc .
+Added: , et al ., No.
+Added: 24-cv-12119 (D.
+Added: The complaint names the Company, Mike Raab, and Justin Renz as defendants and alleges violations of Sections 10(b) and 20(a) the Exchange Act and Rule 10b-5 promulgated thereunder, related to the Company’s announcement on July 2, 2024 that it had chosen not to file an application for Transitional Drug Add-on Payment Adjustment (TDAPA) for XPHOZAH (the “Yarborough Action”).
+Added: The plaintiffs seek damages and interest, and an award of costs, including attorneys’ fees.
+Added: Two shareholders filed motions to be appointed lead plaintiff in the Yarborough Action on October 15, 2024.
+Added: The court has not yet appointed a lead plaintiff.
+Added: We believe the plaintiff’s claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.
+Added: On September 6 and 13, 2024, certain Ardelyx shareholders filed two verified derivative complaints purportedly on behalf of the Company in the United States District Court for the District of Massachusetts alleging violations of Sections 10(b) and/or 14(a) of the Exchange Act, breaches of fiduciary duty, unjust enrichment, waste, and aiding and abetting breaches of fiduciary duty against certain members of our board of directors and management based on substantially the same factual allegations in the Yarborough Action.
+Added: The complaints seek unspecified damages and corporate governance reforms, as well as costs and attorneys’ fees.
+Added: On September 25, 2024, the Court consolidated the two derivative actions into the case In re Ardelyx, Inc.
+Added: Stockholder Derivative Litigation , Case No.
+Added: 1:24-cv-12302-LTS (D.
+Added: We believe the plaintiffs’ claims are without merit and we have not recorded any accrual for a contingent liability associated with these legal proceedings.
From time to time, we may be involved in legal proceedings arising in the ordinary course of business.
−Removed: As of June 30, 2024, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of June 30, 2024.
+Added: As of September 30, 2024, there is no litigation pending that would reasonably be expected to have a material adverse effect on our results of operations and financial condition, and no contingent liabilities were accrued as of September 30, 2024.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.